Samir Siddhanti

Neurocrine Biosciences, Inc. has appointed Samir Siddhanti as its Chief Business Officer and a member of the company's Executive Management Committee. 

In his new role, Siddhanti will lead Neurocrine's enterprise growth strategy, overseeing business development, corporate strategy, alliance management, and program management to maximize the value of the company's expanding pipeline through internal innovation and strategic external partnerships.

Siddhanti has been with Neurocrine Biosciences since 2017, holding leadership positions of increasing responsibility across business development, alliance management, and corporate strategy. Most recently, he served as Vice President of Business Development, where he led numerous strategic transactions and partnerships that strengthened the company's research pipeline and commercial portfolio. Among his notable achievements was leading the company's recent US$2.9 billion acquisition of Soleno Therapeutics, a transaction that further expanded Neurocrine's growth opportunities.

In addition to his business development responsibilities, Siddhanti has served as Program Team Leader for direclidine, providing strategic leadership for the investigational therapy's development in schizophrenia and bipolar disorder while helping shape the company's broader muscarinic receptor portfolio strategy.

Before joining Neurocrine, Siddhanti was a member of the biotechnology equity research team at Goldman Sachs, where he gained extensive experience evaluating life sciences companies and emerging therapeutic opportunities. He holds both Bachelor of Science and Master of Science degrees in Management Science and Engineering from Stanford University.

As Chief Business Officer, Siddhanti will play a central role in advancing Neurocrine Biosciences' long-term growth strategy, supporting pipeline expansion, strategic collaborations, and business development initiatives aimed at bringing innovative therapies to patients with neurological, neuroendocrine, and psychiatric disorders.